Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News September 23rd 2011

September 23rd 2011

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin
Given the high marginal cost of analogue insulin, adherence to prescribing guidelines recommending the preferential use of human insulin would have resulted in considerable financial savings over the period (BMJ open)

Carbohydrate counting sliding scale
Easy and flexible carbohydrate counting sliding scale reduces blood glucose of hospitalized diabetic patient in safety (Diabetes Research and Clinical Practice)

Cochrane review suggests cautious approach when reducing blood glucose in type 2 diabetes
A Cochrane review of 20 randomised controlled trials (RCTs) found that intensive blood glucose control did not significantly reduce all-cause mortality or cardiovascular (CV) mortality, compared with conventional blood glucose control in people with type 2 diabetes (NPC)

Albuminuria and elevated cystatin C linked to cognitive function deficits in patients with diabetes
The results showed that the renal biomarkers ACR and cystatin C were indicative of cognitive impairment in patients with diabetes. Albuminuria was significantly linked to deficits in verbal memory, cystatin C with executive function deficits (DiabetesPro)

The identification of gene expression profiles associated with progression of human diabetic neuropathy
To our knowledge, this is the first study to identify transcriptional changes associated with diabetic neuropathy progression in human sural nerve biopsies and describe their potential utility in classifying diabetic neuropathy. Our results identifying the unique gene signature of patients with progressive diabetic neuropathy will facilitate the development of new mechanism-based diagnostics and therapies (Brain)

Long-Term Metabolic and Immunological Follow-Up of Nonimmunosuppressed Patients With Type 1 Diabetes Treated With Microencapsulated Islet Allografts
The grafts did not elicit any immune response, even in the cases where more than one preparation was transplanted, as a unique finding, compatible with encapsulation-driven “bioinvisibility” of the grafted islets. This result was never achieved with the recipient’s general immunosuppression (Diabetes Care)

1,25(OH)2 Vitamin D Inhibits Foam Cell Formation and Suppresses Macrophage Cholesterol Uptake in Patients With Type 2 Diabetes Mellitus
These results identify reduced vitamin D receptor signaling as a potential mechanism underlying increased foam cell formation and accelerated cardiovascular disease in diabetic subjects (Circulation)

Association of vitamin D receptor gene polymorphisms with insulin resistance and response to vitamin D
This study has highlighted the association of vitamin D responsiveness and insulin resistance with VDR gene polymorphisms. This is the first study to determine associations between all three. Genotyping of the VDR gene may provide a predictive measure for insulin resistance in response to vitamin D intervention (Metabolism – Clinical and Experimental)

Healthy first degree relatives of patients with type 1 diabetes exhibit significant differences in basal gene expression pattern of immunocompetent cells compared to controls: expression pattern as predeterminant of autoimmune diabetes
Our data demonstrate that expression profile of healthy relatives of patients with T1D is clearly distinct from the pattern found in the healthy controls. Thus, we posit that the study of the healthy relative’s gene expression pattern is instrumental for identification of novel markers associated with the development of diabetes (Scandinavian Journal of Immunology)

The management of diabetes in terminal illness related to cancer
A review of the factors influencing blood glucose during terminal illness to provide a suggested approach to managing patients with type 1 and type 2 diabetes during the early and late stages of terminal illness (QJM)

Frost & Sullivan Awards Diabetology Limited Entrepreneurial Company of the Year Award 2011 in Diabetes Therapeutics
Based on their recent analysis of the diabetes therapeutics market, Frost & Sullivan has honoured Diabetology Limited with the European Entrepreneurial Company of the Year Award 2011 in Diabetes Therapeutics (Diabetology)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaBoehringer IngelheimNovo NordiskNapp Diabetes

Silver Sponsors

Abbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership